ClinicalTrials.gg
RecruitingNCT07592299REBOUNDUpdated Nov 12, 2026

To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.

An interventional study of Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System and Control Device: Sham flexible cystoscopy in Benign Prostatic Hyperplasia (BPH), sponsored by ALPFA Medical. Recruiting at 18 sites in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by ALPFA Medical · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now RecruitingFirst site in United States+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Planned enrollment
32nd of 150
250 · median 83
Started
2026
with 14 others
No phase
63 of 188
13 open now
Primary completion
2027-10
later than 29 of 47 live
Registered
182nd of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 32nd largest by planned enrollment of the 150 interventional ones that give a count, is one of 15 that started in 2026, is one of 63 with no phase, reaches primary completion later than 29 of the 47 other live ones, and was the 182nd registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System for treatment of enlarged prostate (BPH) symptoms. The study will involve up to 250 male participants who have urinary problems caused by BPH and whom are greater than 40 years of age in up to 30 investigational centers across the US,Canada and European Union.

Read the detailed description

This study aims to test how safe and effective the ALPFA BPH PFA System is for treating men over age 40 who have urinary problems caused by an enlarged prostate (BPH).The study will involve up to 250 participants in up to 30 investigational centers across the US, Canada, and European Union.

Men who agree to join the study will have health checks before treatment. Those who meet the study eligibility criteria including medication washout requirements,will be placed by chance into one of two groups. Two out of three men will receive treatment with the ALPFA BPH PFA System. One out of three men will receive a sham procedure that looks like treatment but does not deliver treatment.Participants will be followed for longer term safety and effectiveness for a total of 5 years post treatment with the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System.

Patients and site personnel administering follow-up assessments will be blinded to the randomized treatment through completion of the 3-month follow-up visit.

After 3 months, participants will be told which group they were in. Men who were in the sham group may choose to receive treatment with the ALPFA BPH PFA System. Men in the sham group who do not choose treatment by 6 months will no longer take part in the study.

All men who receive treatment will have follow-up visits at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months. After that, they will be checked once a year for up to 5 years.

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)

Browse trials for

Keywords

  • enlarged prostate
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Study subjects are required to meet all the following inclusion criteria to participate in this study as determined by the Investigator:

  1. ≥ 45 years of age on the day of enrollment.
  2. Symptomatic BPH meeting all of the following criteria determined within 30 days preceding enrollment and after fulfilling the concomitant medication (s):

    1. Symptom Score: Baseline IPSS score ≥13
    2. Flow Rate: Uroflow test with a pre-void bladder volume ≥150 mL (confirmed by bladder scan),Single uroflow test with a minimum voided volume ≥ 125 mL and a Qmax ≥ 5 mL/sec and ≤ 15 mL/s
    3. Residual: ultrasound-determined PVR of ≤ 250 mL
  3. Prostate size 25-150 g, measured by transrectal ultrasound.
  4. Willing and able to provide consent and comply with study requirements.

Exclusion Criteria:Subjects will be excluded from the study if they meet any one of the following exclusion criteria, as determined by the Investigator:

  1. Medical conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or confound data or its interpretation, including but not limited to:

    1. Cardiovascular:

      • History of heart failure ( III/IV)
      • Uncontrolled arrhythmia.
      • Stroke, , myocardial infarction, unstable angina, percutaneous coronary intervention, or any cardiac surgery within 180 days of enrollment.
      • Uncontrolled hypertension (> 160 mmHg systolic or > 95 mmHg diastolic on repeat measurements)
    2. Renal: Serum creatinine > 2.0 mg/dL or any history of renal dialysis or renal transplant.
    3. Metabolic: Clinically uncontrolled diabetes mellitus or a baseline ≥ 8.0%, or clinically significant liver disease.
    4. Non-urologic cancer: Active , or within 3 years of enrollment, a history of treated malignancy now in full remission, except basal cell or squamous cell carcinoma of the skin.
    5. Respiratory: Severe lung disease or respiratory illness requiring hospitalization.
    6. : Known immunosuppression, including but not limited to AIDS, immunosuppressive medication, or current chemotherapy.
    7. Transplant: Solid organ or hematologic transplant or currently being evaluated for an organ transplant.
    8. Substance abuse: Active alcoholism or drug addiction.
    9. Sleep apnea: Known moderate to severe obstructive sleep apnea that is untreated or therapy non-compliant
  2. Urologic conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or confound data or its interpretation, including but not limited to:

    1. Operative: Previous prostate surgery or interventional procedure, including but not limited to BPH surgery, radiation, laser, prostate arterial embolism, balloon dilatation, or hyperthermic treatment, or prostate within 40 days of the Index Procedure.
    2. Infection: Urinary tract infection (UTI) (105 CFU/mL) within 90 days of enrollment or >3 UTIs within the year prior to enrollment.
    3. Incontinence: History of urinary incontinence.
    4. Retention: Requires indwelling catheter or intermittent catheterization to void or had an episode of spontaneous urinary retention within 30 days of enrollment.
    5. Prostatitis: History of prostatitis or chronic pelvic pain syndrome (CPPS) within 2 years of enrollment.
    6. Cystolithiasis: Active bladder stones
    7. Neurogenic bladder: Neurogenic or atonic bladder or sphincter, including etiologies of uncontrolled diabetes, Parkinson's disease, multiple sclerosis, cerebrovascular accident, or polyneuropathy.
    8. Anatomic abnormality: Prior or current urethral stricture, meatal stenosis, bladder neck contracture, or other urologic anatomic abnormalities that would interfere with planned treatment or confound subsequent assessment.
    9. Implants: Any urinary tract implants including stents, sutures, penile implants, or artificial sphincters.
    10. Hematuria: Hematuria without a known contributing factor within 90 days of the Index Procedure.
  3. Bladder cancer: Actively being treated or suspected cancer of the bladder.
  4. Prostate cancer:

    1. Confirmed or history of prostate cancer
    2. Baseline PSA > 15 ng/mL within 30 days of enrollment
    3. If PSA is between 4.0 ng/mL and 15 ng/mL, prostate cancer must be ruled out with a negative biopsy or an MRI (≤PIRADS-3) within 12 months prior to enrollment.
  5. Prior pelvic or rectal interventions:

    1. Previous pelvic irradiation or radical pelvic surgery
    2. Previous rectal surgery (other than hemorrhoidectomy) or a history of rectal disease that may be impacted by Index Procedure.
  6. Peri-procedural anticoagulation: Unable to stop anti- or anticoagulation treatment for the Index Procedure per site standard of care.
  7. Subjects who cannot or will not comply with the following washout medication requirements within the time period specified prior to enrollment:

    1. 24-Hours:

      • i. Taking phenylephrine or pseudoephedrine within 24 hours of the Baseline evaluation and Index Procedure.
    2. 1 Week:

      • i. Antihistamine, anticonvulsant, or antispasmodics medications within 1 week of enrollment unless documented on a stable (unchanged) dose for 180 days prior to enrollment.
    3. 2 Weeks:

      • i. Use of alpha blockers or daily dosage of PDE5 inhibitors (tadalafil [Cialis]) for BPH within 2 weeks prior to enrollment.
      • ii. Use of anticholinergics or beta-3 adrenergic receptor agonists (e.g., mirabegron, vibegron) within 2 weeks prior to enrollment, unless documented on a stable dose for 30 days prior to enrollment.
    4. 3 Months:

      • i. Taking estrogen, drugs producing androgen suppression, or androgens within 90 days prior to enrollment, unless documented on a stable dosage for at least 180 days prior to enrollment.
      • ii. Use of Type II 5-alpha reductase inhibitor medication (e.g., finasteride [Proscar, Propecia]) within 90 days of enrollment OR anticipated use within the first 12 months of follow-up.
    5. 6 Months:

      • i. Use of any Type I 5-alpha reductase inhibitor medication (e.g., dutasteride [Avodart]) within 180 days prior to enrollment OR anticipate use within the first 12 months of follow-up.
      • ii. Taking tricyclic antidepressants that are not on a stable dose for the 180 days prior to enrollment OR anticipate stopping or changing treatment in the first 12 months of follow-up.
  8. Subjects who wish to maintain their fertility.
  9. Current or anticipated enrollment in any other randomized or interventional clinical study (registry or retrospective studies permitted).
  10. Vulnerable populations, including individuals who are incarcerated or institutionalized.Any physical, psychological, or developmental impairment (e.g., developmental delay) that, in the investigator's opinion, would compromise the subject's ability to provide , comply with study procedures, or complete patient-reported outcome measures.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Treatment Device

    Men who join the study will first have a health check to see if they can take part. If they meet the study requirements and have stopped any restricted medications, they will be assigned by chance to a treatment group and treated with the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System(Treatment) per their randomized assignment. Participants will then have follow-up visits with health checks as planned for this study

    Device: Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System

  • Sham comparator
    Control Device

    Men who join the study will first have a health check to see if they can take part. If they meet the study requirements and have stopped any restricted medications, they will be assigned by chance to a control group and treated with sham flexible cystoscopy (Control) per their randomized assignment. Participants will then have follow-up visits with health checks as planned for this study

    Device: Control Device: Sham flexible cystoscopy

  • Other
    Crossover Cohort

    Control Arm (Sham) patients can receive treatment with the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System after their 3-month follow-up assessments are completed, and participant symptom profile necessaites treatment and alll protocol defined enrollment criteria are met. The study visit follow-up schedule will restart and the subject will be followed for 60 months post ALPFA GRAIL™ Pulsed Field Ablation (PFA) System(Treatment)Unless treated with the ALPFA GRAIL™ Pulsed Field Ablation(PFA)System, the subject will be exited from the study once they have completed their 3-month follow-up visit.

    Device: Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System

Interventions

  • DeviceTreatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System

    After the participant receives anesthesia, the Investigator will proceed with placement of the ALPFA GRAIL PFA Catheter into the prostate via a standard flexible cystoscope. Visualization of the prostatic urethra will determine the number of balloons that are exposed and inflated. When the catheter has been properly positioned, the ALPFA GRAIL PFA Console will be activated and one PFA application will be delivered. The Investigator will assess if the catheter needs to be repositioned and additional ablation applications delivered, as necessary. Once ablation is complete, the catheter balloons will be deflated, and the catheter will be withdrawn from the urethra. Participants will then have follow-up visits with health checks as planned for this study.

  • DeviceControl Device: Sham flexible cystoscopy

    Participants will receive mock treatment with a flexible cystoscope with a working channel that is at least 6.9F in diameter. The cystoscope will be inserted and treatment script initiated. Once the script is completed, the cystoscope will be removed and procedural details captured on the relevant CRF. Participants will then have follow-up visits with health checks as planned for this study.

06

What researchers measure

Primary outcomes

  1. Safety-Incidence of Serious Device-or Procedure-Related Adverse Events (Composite Safety Endpoint)

    The primary safety endpoint is the proportion of participants experiencing one or more of the following serious device-related or procedure-related adverse event through 12 months post-procedure

    Time frame: Through 12 months post-procedure

  2. Effectiveness-Change from Baseline in International Prostate Symptom Score (IPSS) at 3 Months.

    The International Prostate Symptom Score (IPSS) is a 7-item questionnaire (score range 0-35) where higher scores indicate more severe symptoms. Success is defined as the Treatment group showing a 25% greater relative improvement in mean score compared to the Control group

    Time frame: Baseline to 3 months post-procedure

  3. Effectiveness-Durability of Treatment Effect: Percent Change in International Prostate Symptom Score (IPSS) at 12 Months

    This endpoint evaluates the long-term effectiveness of the ALPFA GRAIL PFA System. It is calculated as the mean percentage change in the total International Prostate Symptom Score (IPSS) score from the start of the study (baseline) to the 12-month follow-up for participants in the treatment group.

    Time frame: Baseline to 12 months post-procedure

Secondary outcomes

  1. Additional Study Goals

    1.Comparison of Symptom Improvement (at 3 Months) Researchers will compare the average change in prostate symptoms between the group that received the study treatment and the control group. This helps show if the treatment provides more relief than the standard comparison.

    Time frame: 3 months

  2. Success Stories (Responder Rate)

    2\. Number of "Success Stories" (Responder Rate) The study will count how many participants had a meaningful improvement in their symptoms. A "responder" (a success) is defined as a person whose symptoms improved by at least 30% three months after the treatment.

    Time frame: 3 months

  3. Improvement in Urine Flow

    3\. Improvement in Urine Flow (Qmax) Researchers will measure the strength of the participant's urine flow. They will compare the average change in flow strength from the start of the study to three months later between the treatment group and the control group.

    Time frame: 3 months

07

Study locations

17 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Aug 2026 → Oct 2026 and primary completion Aug 2028 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 18, 2026
StartActual
Oct 28, 2026was Aug 2026
Primary completionEst.
Oct 2027was Aug 2028
CompletionEst.
Dec 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
18 sites added — first site in United States
Show 18 added (18 United States)
  • The Conrad Pearson Clinic · Germantown, United States
  • East Valley Urology · Mesa, United States
  • Academic Urology & Urogynecology of Arizona · Sun City, United States
  • Del Sol Research Management · Tucson, United States
  • Oefelien Clinical Trials · Bakersfield, United States
  • San Diego Clinical Trials · La Mesa, United States
  • Golden State Urology · Sacramento, United States
  • Urology Associates - Lone Tree · Lone Tree, United States
  • Gulf Coast Clinical Trial Associates · Tampa, United States
  • Avant Concierge Urology · Winter Garden, United States
  • Capital Surgical Associates · Meridian, United States
  • Comprehensive Urology · Lake Barrington, United States
  • Southern Urology · Lafayette, United States
  • Kearney Urology Center · Kearney, United States
  • The Smith Institute of Urology Northwell Health · Plainview, United States
  • Urology Austin PLLC · Austin, United States
  • The Urology Place · San Antonio, United States
  • Midtown Urology Associates · West Lake Hills, United States
across 2 updates, Oct 15, 2026 – Nov 12, 2026
Start date
Aug 2026→Oct 2026
Oct 15, 2026
Primary completion
Aug 2028→Oct 2027
Oct 15, 2026
Eligibility
4 criteria edited, 7 added, 3 removed
What changed in the criteria
  • EditedFlow Rate: Uroflow test with a pre-void bladder volume ≥150 mL (confirmed by bladder scan),Single uroflow test with a minimum voided volume ≥ 125 mL and a Qmax ≥ 5 mL/sec and ≤ 1215 mL/s
  • RemovedUncontrolled hypertension
  • AddedUncontrolled hypertension (> 160 mmHg systolic or > 95 mmHg diastolic on repeat measurements)
  • AddedSleep apnea: Known moderate to severe obstructive sleep apnea that is untreated or therapy non-compliant
  • RemovedInfection: Active urinary tract infection at the time of the Index Procedure (may be treated and enrolled upon negative urine culture).
  • AddedInfection: Urinary tract infection (UTI) (105 CFU/mL) within 90 days of enrollment or >3 UTIs within the year prior to enrollment.
  • EditedProstatitis: History of prostatitis or chronic pelvic pain syndrome (CPPS) within 2 years of enrollment.
  • RemovedBaseline PSA > 10 ng/mL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng/mL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction following the site's standard of care.
  • AddedProstate cancer:
  • AddedConfirmed or history of prostate cancer
  • AddedBaseline PSA > 15 ng/mL within 30 days of enrollment
  • AddedIf PSA is between 4.0 ng/mL and 15 ng/mL, prostate cancer must be ruled out with a negative biopsy or an MRI (≤PIRADS-3) within 12 months prior to enrollment.
  • Editedi. Antihistamine, anticonvulsant, or antispasmodics medications within 1 week of enrollment unless documented on a stable (unchanged) dose for 180 days prior to enrollment.
  • Editedi. Taking estrogen, drugs producing androgen suppression, or androgens within 90 days prior to enrollment, unless documented on a stable dosage for at least 90180 days prior to enrollment.
Oct 15, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameSafety-Incidence of Serious Device-or Procedure-Related Adverse Events (Composite Safety Endpoint)Through 90 days post-procedure → Through 12 months post-procedure
  • DescriptionSafety-Incidence of Serious Device-or Procedure-Related Adverse Events (Composite Safety Endpoint): how it is measured was reworded
Oct 15, 2026
Contact
Study contact changed: a•••@alpfamedical.com · •••9550→e•••@alpfamedical.com · •••0658. See the current contact
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Conrad Pearson Clinic · Germantown, United StatesContact W•••@conradpearson.com→W•••@conradpearson.comContact removed (no phone or email listed)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    17 sites added
    Show 17 added (17 United States)
    • East Valley Urology · Mesa, United States
    • Academic Urology & Urogynecology of Arizona · Sun City, United States
    • Del Sol Research Management · Tucson, United States
    • Oefelien Clinical Trials · Bakersfield, United States
    • San Diego Clinical Trials · La Mesa, United States
    • Golden State Urology · Sacramento, United States
    • Urology Associates - Lone Tree · Lone Tree, United States
    • Gulf Coast Clinical Trial Associates · Tampa, United States
    • Avant Concierge Urology · Winter Garden, United States
    • Capital Surgical Associates · Meridian, United States
    • Comprehensive Urology · Lake Barrington, United States
    • Southern Urology · Lafayette, United States
    • Kearney Urology Center · Kearney, United States
    • The Smith Institute of Urology Northwell Health · Plainview, United States
    • Urology Austin PLLC · Austin, United States
    • The Urology Place · San Antonio, United States
    • Midtown Urology Associates · West Lake Hills, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Conrad Pearson Clinic · Germantown, United StatesContact W•••@conradpearson.com→W•••@conradpearson.comContact removed (no phone or email listed)
    + 2 other changes: verification date and date precision
  2. Oct 15, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • The Conrad Pearson Clinic · Germantown, United States
    Start date Aug 2026→Oct 2026
    Primary completion Aug 2028→Oct 2027
    Eligibility 4 criteria edited, 7 added, 3 removed
    What changed in the criteria
    • EditedFlow Rate: Uroflow test with a pre-void bladder volume ≥150 mL (confirmed by bladder scan),Single uroflow test with a minimum voided volume ≥ 125 mL and a Qmax ≥ 5 mL/sec and ≤ 1215 mL/s
    • RemovedUncontrolled hypertension
    • AddedUncontrolled hypertension (> 160 mmHg systolic or > 95 mmHg diastolic on repeat measurements)
    • AddedSleep apnea: Known moderate to severe obstructive sleep apnea that is untreated or therapy non-compliant
    • RemovedInfection: Active urinary tract infection at the time of the Index Procedure (may be treated and enrolled upon negative urine culture).
    • AddedInfection: Urinary tract infection (UTI) (105 CFU/mL) within 90 days of enrollment or >3 UTIs within the year prior to enrollment.
    • EditedProstatitis: History of prostatitis or chronic pelvic pain syndrome (CPPS) within 2 years of enrollment.
    • RemovedBaseline PSA > 10 ng/mL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng/mL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction following the site's standard of care.
    • AddedProstate cancer:
    • AddedConfirmed or history of prostate cancer
    • AddedBaseline PSA > 15 ng/mL within 30 days of enrollment
    • AddedIf PSA is between 4.0 ng/mL and 15 ng/mL, prostate cancer must be ruled out with a negative biopsy or an MRI (≤PIRADS-3) within 12 months prior to enrollment.
    • Editedi. Antihistamine, anticonvulsant, or antispasmodics medications within 1 week of enrollment unless documented on a stable (unchanged) dose for 180 days prior to enrollment.
    • Editedi. Taking estrogen, drugs producing androgen suppression, or androgens within 90 days prior to enrollment, unless documented on a stable dosage for at least 90180 days prior to enrollment.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameSafety-Incidence of Serious Device-or Procedure-Related Adverse Events (Composite Safety Endpoint)Through 90 days post-procedure → Through 12 months post-procedure
    • DescriptionSafety-Incidence of Serious Device-or Procedure-Related Adverse Events (Composite Safety Endpoint): how it is measured was reworded
    Contact Study contact changed: a•••@alpfamedical.com · •••9550→e•••@alpfamedical.com · •••0658. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07592299
Lead sponsor
ALPFA Medical
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Oct 28, 2026
Primary completion
Oct 2027 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Elizabeth Dravis
Contact
edravis@alpfamedical.com
+1. 713.819.0658
Jaya Kothule
Contact
jkothule@alpfamedical.com
+1 408.480.2859
Dr. Bilal Chughtai
principal investigator · The Smith Institute of Urology/Northwell Health
Dr. Dean Elterman
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion